19 results about "Erythropoietin" patented technology

This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and / or have MDS relapsed / refractory to Erythropoiesis-Stimulating Agent (ESA).

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

To provide an agent for reducing iron overload in patients having conditions such as beta-thalassaemia and myelodysplastic syndrome (MDS).SOLUTION: Antibodies to enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to a serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoeitin, provides additional therapeutic effects.SELECTED DRAWING: Figure 1

Methods and systems are disclosed for assisting with the management of anemia in a patient. In some examples, the method includes accessing patient parameters associated with the patient, wherein the patient parameters include an aligned hemoglobin time series for the patient generated from multiple measurement sources. The method then includes accessing a physiology-based model and adapting the physiology-based model into a patient specific model that predicts future hemoglobin levels for the patient based on one or more erythropoiesis-stimulating agent (ESA) dosing regimens, wherein adapting the physiology-based model to the patient specific model utilizes the patient parameters, and generates estimates of patient-specific physiological characteristics. The method then includes running simulations with the patient specific model and determining a recommended ESA dose. The recommended ESA dose that the model predicts will cause either or both of the patient's hematocrit or hemoglobin concentration to reach a desired range within a specified time frame.

The invention belongs to the field of medicines, and particularly discloses an application of a scutellaria baicalensis stem and leaf extract, and the scutellaria baicalensis stem and leaf extract has a good effect on treating anemia induced by ulcerative colitis and improving erythropoietin.

The invention discloses application of recombinant human erythropoietin in preparation of a medicine for preventing and treating plateau pulmonary edema. In the construction process of the mouse plateau pulmonary edema model, the recombinant human erythropoietin drug treatment group can reduce the edema level of the mouse plateau pulmonary edema; meanwhile, the expression of inflammatory factors TNF-alpha and IL-6 in lung tissues can be inhibited in a plateau pulmonary edema model; mouse lung function detection finds that the lung function can be improved; lung tissue HE staining shows that the recombinant human erythropoietin can also relieve the exudation level of the lung tissue structure.

Methods and systems are disclosed for assisting with the management of anemia in a patient. In some examples, the method includes accessing patient parameters associated with the patient, wherein the patient parameters include an aligned hemoglobin time series for the patient generated from multiple measurement sources. The method then includes accessing a physiology-based model and adapting the physiology-based model into a patient specific model that predicts future hemoglobin levels for the patient based on one or more erythropoiesis-stimulating agent (ESA) dosing regimens, wherein adapting the physiology-based model to the patient specific model utilizes the patient parameters, and generates estimates of patient-specific physiological characteristics. The method then includes running simulations with the patient specific model and determining a recommended ESA dose. The recommended ESA dose that the model predicts will cause either or both of the patient's hematocrit or hemoglobin concentration to reach a desired range within a specified time frame.

Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.

The present invention relates to a method for producing red blood cells, and more specifically, to (S1) culturing pluripotent stem cells to obtain a culture medium containing hematopoietic stem cells, and (S2) obtaining CD41 from the culture medium. - and CD34 - The present invention relates to a method for producing red blood cells of superior quality in a short period of time, comprising the steps of (S3) obtaining a cell population and (S3) maturing the obtained cell population in a first medium containing erythropoietin.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and / or anemia.

The present invention relates to the treatment of physiologic iron overload and provides antibodies against the proteolysis 2 (MTP-2). Inhibition of MTP-2 reduces dietary iron uptake and reduces iron release from cellular stores in the body. Inhibitors of MTP-2, such as antibodies against the serine protease domain, are useful in the treatment of iron overload, which is characteristic of diseases such as beta-thalassemia and which would otherwise lead to toxic accumulation of iron. Combinations of MTP-2 inhibitors with activin receptor ligand traps or with erythropoietin provide additional therapeutic effects.

This invention belongs to the field of pharmaceutical analysis technology, specifically relating to a method for detecting the content of poloxamer 188 in human erythropoietin injection. The method provided by this invention employs high-performance liquid chromatography (HPLC). Using a tandem size exclusion column and a cation exchange column, poloxamer 188 is separated and eluted from human erythropoietin protein and other excipients in the formulation. Detection is performed using a differential refractive index detector. Simultaneously, a poloxamer 188 standard is injected, and the content of poloxamer 188 in the formulation is calculated using the external standard method. The detection method provided by this invention has the advantages of simple operation, strong applicability, high accuracy, and no need for sample pretreatment. It can rapidly detect the poloxamer content in human erythropoietin and other protein formulations, enabling better control of drug quality.

The present disclosure belongs to the field of biological medicines, and relates to an inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells uses human mesenchymal stem cell serum-free culture medium as a substrate and comprises the following components in mass concentration ratios: 20-60 mg / L of bone morphogenetic protein-4, 20-60 mg / L of bone morphogenetic protein-7, 2-8 mg / L of retinoic acid, 2-8 mg / L of resveratrol, 2-8 mg / L of icariin, 2-8 μg / L of benzamide, 2-8 μg / L of chloroplatinic acid hexahydrate, 2-8 μg / L of ethanolamine, 2-10 μg / L of erythropoietin and 2-10 μg / L of vascular endothelial growth factor. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells provided by the present disclosure has a high induction efficiency.

Antibodies against the protease 2 (MTP-2) are provided. Inhibition of MTP-2 reduces dietary iron uptake and reduces release of iron from cellular stores in the body. Inhibitors of MTP-2, such as antibodies against the serine protease domain, are useful in the treatment of iron overload, which is characteristic of diseases such as beta-thalassemia and would otherwise result in toxic accumulation of iron. Combinations of MTP-2 inhibitors with activin receptor ligand traps or with erythropoietin provide additional therapeutic effects.

Anemia, defined as a reduction in the amount of functional red blood cells in circulation, is a major cause of disease affecting one-third of the world's population. Iron is essential for hemoglobin, the functional component of red blood cells, to store and transport oxygen. Hepcidin, a liver-derived peptide, is a key regulator of iron homeostasis. During anemia, the erythropoietic hormone erythroferon regulates hepcidin synthesis to ensure an adequate supply of iron to the bone marrow for red blood cell synthesis. However, accumulating evidence suggests that other factors may perform a similar function. We identified the hepatokine FGL1 as a previously undescribed hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent hepcidin suppressor in vitro and in vivo. Deletion of Fgl1 in mice blunts hepcidin suppression after hemorrhage.Finally, FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the BMP-SMAD signaling cascade that controls hepcidin regulation.Therefore, the present invention relates to an FGL1 polypeptide for use in treating patients suffering from iron deficiency-related diseases.

The present application relates to the technical field of antigen-antibody proteins, in particular to anti-human mutant erythropoietin mouse monoclonal antibody, application and human recombinant erythropoietin stimulant detection method. The hybridoma cell strain has a preservation number of CGMCC No.45302, and the mouse monoclonal antibody secreted and expressed by the hybridoma cell strain can specifically recognize human mutant erythropoietin p.Arg193AspfsTer28. A two-way immunopurification combined with a protein immunoblotting technology established by using the mouse monoclonal antibody can be used as a human urine sample recombinant erythropoietin stimulant detection method, can effectively distinguish wild-type erythropoietin, mutant erythropoietin and recombinant erythropoietin in human urine samples, can directly and accurately detect recombinant erythropoietin in urine samples from various populations, can exclude false positive risks, can optimize the stimulant detection process, and can make up for the defects in the current world anti-stimulant field about recombinant erythropoietin detection.

The application relates to the fields of medical care informatics and precision medical technology, and discloses a precision medication system for hemodialysis patients based on multiple omics and big data, which comprises the following modules: a multi-source data acquisition module, which acquires multi-source heterogeneous data of patients and performs standardization and integration processing; a drug metabolism analysis module, which analyzes drug metabolism pathways and individual differences through multi-omics data, constructs a drug metabolism polymorphism model, and outputs gene metabolism capacity classification and biomarker risk labels; an initial medication decision module, which is used for constructing an initial medication decision model based on a federal optimization framework of momentum enhancement and robust aggregation mechanism, and outputting a personalized initial medication scheme for erythropoietin and intravenous iron agents; and a drug dose adjustment module, which is used for dynamically optimizing time nodes and dose adjustment opportunities of drug administration through an asynchronous federal reinforcement learning framework combined with a forward-looking parameter correction strategy. The application constructs an intelligent medication system with strong robustness and fine decision.

The present invention relates to the fields of Biotechnology and Medicine and describes a pharmaceutical composition of recombinant human erythropoietin which is characterized by having a microheterogeneity of fucosylated N-glycans formed by bi, tri and tetra-antennary structures with mono and bi-sialylated sialic acid residues that represent 40-60% of the total glycans, trisialylated ones that represent 40-43% of the total glycans and tetrasialylated ones that represent 10-13% of the total glycans. This glycosylation pattern confers properties to said composition that allow for its use in disorders of the nervous system. The method of obtaining the pharmaceutical composition described herein is also described.

The present invention relates to the substance sebparin or a pharmaceutically acceptable salt thereof for use in the treatment of subjects with chronic kidney disease (CKD), which may also include anemia. This therapy may also be useful as a combination therapy with standard of care (SOC) therapies, such as erythropoiesis-stimulating agents (ESAs) or HIF prolyl hydroxylase inhibitors.